Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.

scientific article published on 21 March 2017

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/MIB.0000000000001074
P698PubMed publication ID28328624

P50authorChristopher MaQ49218919
Vivian W. HuangQ53196309
Subrata GhoshQ59832001
Remo PanaccioneQ92078930
P2093author name stringBrendan P Halloran
Richard N Fedorak
Gilaad G Kaplan
Yvette Leung
Cynthia H Seow
Karen Wong
Shane M Devlin
Levinus A Dieleman
Kerri L Novak
Karen I Kroeker
Nathan Stern
Philip K Blustein
P2860cites workIncreasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic ReviewQ22250934
Ustekinumab in Crohn's disease: evidence to date and place in therapyQ28073787
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialQ28202504
Certolizumab pegol for the treatment of Crohn's diseaseQ28236746
A simple index of Crohn's-disease activityQ28259898
A genome-wide association study identifies IL23R as an inflammatory bowel disease geneQ28270603
Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseQ30054715
Radiographic imaging of inflammatory bowel diseaseQ34139421
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trialQ34574245
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsQ36477912
Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapyQ37871625
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.Q38572827
The global burden of IBD: from 2015 to 2025.Q38577572
Patients with Refractory Crohn's Disease Successfully Treated with UstekinumabQ38692257
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experienceQ39164487
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.Q40472089
Loss of Response to Anti-TNFs: Definition, Epidemiology, and ManagementQ40994357
Ustekinumab induction and maintenance therapy in refractory Crohn's diseaseQ42514321
Development of the Crohn's disease digestive damage score, the Lémann scoreQ42759984
Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.Q45200648
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.Q50237402
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.Q53540951
Infliximab, azathioprine, or combination therapy for Crohn's diseaseQ56988763
Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysisQ57910344
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort studyQ59120257
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of ResponseQ59120277
P433issue5
P921main subjectCrohn's diseaseQ1472
P304page(s)833-839
P577publication date2017-05-01
P1433published inInflammatory Bowel DiseasesQ15749161
P1476titleLong-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study
P478volume23

Reverse relations

cites work (P2860)
Q92859154Biologic therapies for Crohn's disease: optimising the old and maximising the new
Q49218809Clinical utility of ustekinumab in Crohn's disease.
Q90055639Early real-world effectiveness of ustekinumab for Crohn's disease
Q48336044Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?
Q57788239Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease
Q50012048Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease
Q90656440Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study
Q53075985Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series.
Q92895315Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Q93184539Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease

Search more.